NEW YORK, Jan. 8 — MorphoSys said Tuesday that it would expand its drug target identification and validation partnership with Cambridge, Mass.-based Biogen.
Under the two companies' initial agreement, inked one year ago, MorphoSys provides Biogen with research antibodies against expressed sequence tags for drug target validation. The new agreement increases the number of ESTs in the deal, and allows Biogen access to MorphoSys' new HuCAL GOLD library.
Through the old partnership, Biogen paid MorphoSys an upfront technology access fee and for use of the HuCAL technology. Biogen also agreed to make milestone and royalty payments for any antibody-based therapeutics.
By this updated agreement, MorphoSys will receive additional research and licensing payments. Financial details were not disclosed.
Munich-based MorphoSys develops technologies for synthetic antibody production and produces human antibodies for use in drug development.
Biogen will be the first partner to access this version of the MorphoSys library, said the company.